Siderophores are natural iron-chelating molecules that are produced and released by nearly all bacterial species to facilitate the transport of iron into the bacterial cell for survival and growth. Siderophore molecules may be covalently linked to chemical moieties with antibacterial activity, and are then known as sideromycins. For example, albomycin is a naturally occurring sideromycin, and contains a ferrichrome siderophore group and a thioribosyl pyrimidine antibiotic \[[@CIT0001]\]. Albomycin is taken up by the bacterial cell via an active transport system through the outer membrane, a mechanism that overcomes the problem of poor permeability of the outer membrane of gram-negative bacteria to antibiotics. Research into sideromycins has revealed that the involvement of an active transport system results in greater susceptibility to antibiotics and lower minimum inhibitory concentrations (MICs) compared with those molecules that are transported through the outer membrane via a passive or other mechanism \[[@CIT0001]\].

Based on these observations, research into synthetic β-lactams conjugated with siderophores was started in the 1980s \[[@CIT0002]\]. Several pharmaceutical companies have identified siderophore-conjugated antibiotics with potent in vitro antibacterial activity against gram-negative bacteria, including *Pseudomonas aeruginosa*. The siderophore moiety of the conjugates sequesters environmental iron, and then the iron--siderophore--antibiotic complex binds to an iron transporter outer membrane protein and is actively taken up \[[@CIT0007]\]. This mechanism is called a "Trojan horse" strategy, enabling more efficient penetration by overcoming certain intrinsic or acquired antibiotic resistance mechanisms \[[@CIT0007], [@CIT0008]\]. Following entry into the periplasmic space of the bacterial cell, the complex needs to dissociate for the antibiotic to exert its antibacterial activity \[[@CIT0008]\].

Past efforts to advance selected siderophore cephalosporin candidates, such as GR69153 (cefetecol, a catechol-substituted cephalosporin) and M-14659 (an antipseudomonal cephalosporin) ([Figure 1](#F1){ref-type="fig"}), into clinical-stage development were not successful, despite demonstration of potent activity in vitro \[[@CIT0011], [@CIT0012]\]. In the early 1990s, Shionogi & Co, Ltd (Osaka, Japan) identified the siderophore cephalosporin S-9096, which had potent antibacterial activity against gram-negative pathogens, including *P. aeruginosa* \[[@CIT0013], [@CIT0014]\]. This compound possesses a catechol moiety at the C-3 side chain, resulting in good permeability of the outer membrane of gram-negative bacteria by utilizing ferric iron transport systems. However, S-9096 did not progress to clinical development because of cardiovascular toxicity and low substance stability (unpublished data).

![Structures of synthetic siderophore-conjugated β-lactams and cephalosporins.](ciz826f0001){#F1}

DISCOVERY AND CHEMISTRY OF CEFIDEROCOL {#s1}
======================================

After more than 15 years, Shionogi resumed the search for novel siderophore cephalosporins. At this time, reports of carbapenem resistance had threatened the effectiveness of available treatment options and thus represented a great and growing unmet medical need \[[@CIT0015]\]. Thus, the research focused on chemical compositions that could provide improved stability to clinically important and prevalent β-lactamases, including metallo-β-lactamases (MBLs). In addition, it was important that their in vitro potency could be translated into in vivo efficacy in animal infection models and supported by advantageous pharmacokinetic/pharmacodynamic (PK/PD) relationship. Shionogi's focus on the development of a siderophore cephalosporin with a catechol moiety contrasted with the research efforts in monobactams, which used a hydroxypyridone siderophore moiety (BAL30072, MB-1, SMC-3176) \[[@CIT0007], [@CIT0008], [@CIT0016]\]. Of note, the natural siderophores enterobactin and pyoverdine produced by *Escherichia coli* and *P. aeruginosa*, respectively, are also catechol substituted molecules \[[@CIT0019]\]. The investigations by Shionogi led to the identification of cefiderocol (formerly S-649266, GSK2696266) \[[@CIT0019]\]. The structure--activity relationship of numerous chemical compositions related to cefiderocol has been described in detail by Aoki et al \[[@CIT0019]\]. Cefiderocol is similar to cefepime in that it has a pyrrolidinium group on the C-3 side chain, which improves antibacterial activity and stability against β-lactamases ([Figure 2](#F2){ref-type="fig"}). Additionally, similarly to ceftazidime, cefiderocol has a carboxypropanoxyimino group on the C-7 side chain, which improves transport across the outer membrane ([Figure 2](#F2){ref-type="fig"}) \[[@CIT0019]\]. The major difference in the chemical structure of cefiderocol and ceftazidime or cefepime is the addition of a chlorocatechol group on the end of the C-3 side chain, which confers the siderophore activity. Of note, the methoxy form of the chlorocatechol group has reduced antibacterial activity because it is unable to chelate iron, thus it is not transported efficiently into bacteria \[[@CIT0020]\]. Investigation of the structure--activity relationship has revealed that modifications on both the C-7 and C-3 side chains contribute to the increased potency against drug-resistant gram-negative bacteria by conferring stability against β-lactamases, including carbapenemases, while maintaining high affinity to the molecular target, the penicillin-binding proteins (PBPs) \[[@CIT0019], [@CIT0021], [@CIT0022]\].

![Structure--activity relationships for cefiderocol. Abbreviation: PBP, penicillin-binding protein.](ciz826f0002){#F2}

MECHANISM OF ACTION {#s2}
===================

As with other β-lactam antibiotics, cefiderocol exerts a primary effect on cell wall synthesis by inhibiting PBPs, which results in cell death \[[@CIT0022]\]. Similarly to other cephalosporin antibiotics such as ceftazidime, cefiderocol showed potent in vitro bactericidal activity in time-kill curve experiments against 4 main bacterial pathogens---*Klebsiella pneumoniae*, *E. coli*, *P. aeruginosa*, and *Acinetobacter baumannii*---as a result of the high binding affinities, primarily to PBP3 \[[@CIT0022]\].

Carbapenem-resistant strains of gram-negative bacteria are genetically diverse and may harbor multiple resistance mechanisms, such as carbapenemase production and lower outer membrane permeability due to reduced expression or conformational mutations of porin channels and/or the upregulation of efflux pumps \[[@CIT0023]\]. However, the abovementioned key features have enabled cefiderocol to overcome these resistance mechanisms.

Additional investigation into the mechanism of action of cefiderocol has revealed that the specific outer membrane iron transporters CirA and Fiu in *E. coli* and PiuA in *P. aeruginosa* are involved in the active transport of cefiderocol \[[@CIT0020], [@CIT0022]\]. Strains with mutations that result in deficiency in the activity of these transporter molecules showed significantly increased MICs (ie, ≥16-fold). Other siderophore-conjugated β-lactams, such as GR69153, BMS180680, MC-1, and SMC-3176, showed similarly reduced effects against mutant strains, with the exception of cefiderocol activity to *P. aeruginosa*, which is unaffected by the deficiency of PirA \[[@CIT0011], [@CIT0018], [@CIT0022], [@CIT0024]\]. The active transport process of the cefiderocol--ferric iron complex is not fully understood, and other transport determinants specific for cefiderocol might exist. This active transport mechanism contributes to not only to deliver cefiderocol efficiently into the periplasmic space where the target PBPs are located but also overcomes permeability-related drug resistance due to porin channel loss and overexpression of multidrug efflux pumps. Further investigation has revealed that cefiderocol potency for *K. pneumoniae* mutants with defects in the porin genes *ompK35* and/or *ompK36* resulted in only a 2- to 4-fold increase in MIC, whereas simultaneous mutations in these porin channels increased the MIC for meropenem 8-fold compared with that of the parent strain \[[@CIT0022], [@CIT0027], [@CIT0028]\]. Similarly, against *P. aeruginosa*, cefiderocol MIC was little affected by the defect (ie, Tn insertion mutation) in carbapenem permeation porin protein *oprD* or the overproduction of MexA-MexB-OprM multidrug efflux pump due to a defect in the *mexR* or *nalD* regulator gene \[[@CIT0022]\]. Additionally, the change in cefiderocol MIC values may result from the deficiency of the components of the efflux pump compared with that of the PAO1 parent strain, regardless of the absence or presence of iron in the media \[[@CIT0022]\]. The data currently suggest that the influence of efflux pumps and porin channels on the in vitro activity of cefiderocol is insignificant.

Another key feature of cefiderocol is the intrinsic structural stability against a wide range of serine- and metallo-β-lactamases such as *K. pneumoniae* carbapenemase (KPC), oxacillin carbapenemase (OXA), New Delhi metallo-β-lactamase (NDM), and Verona integron-encoded metallo-β-lactamase (VIM) carbapenemase \[[@CIT0021], [@CIT0029]\]. The catalytic efficiencies (*k*~cat~/*K*~*m*~) of MBLs of VIM-2, imipenemase metallo-β-lactamase (IMP) 1, and L1 for cefiderocol were quite low, ≥260-fold lower than those for meropenem, and only a low rate of hydrolysis of cefiderocol by KPC-3 was observed \[[@CIT0021]\]. The relative hydrolysis velocity of cefiderocol by NDM-1 was approximately 3--10 times lower than that of meropenem, ceftazidime, or cefepime \[[@CIT0021]\]. Additionally, no or very weak hydrolysis of cefiderocol was observed by class D serine-carbapenemases such as OXA-48, OXA-40, and OXA-23 \[[@CIT0029]\]. Regarding the class C β-lactamases (noncarbapenemase enzymes, which could lead to carbapenem resistance when overproduced), cefiderocol had 40-fold and \>940-fold lower affinity to ampicillin chromosomal cephalosporinase (AmpC) β-lactamases of *P. aeruginosa* SR24-12 and *Enterobacter cloacae* P99, respectively, compared with ceftazidime \[[@CIT0030]\]. The MIC of cefiderocol was not elevated against *P. aeruginosa* that overproduced AmpC due to mutation of the *dacB* gene (the gene coding [d]{.smallcaps}-alanyl-[d]{.smallcaps}-alanine carboxypeptidase) \[[@CIT0030]\]. Cefiderocol also has a low propensity of AmpC induction in both bacterial species, similar to other oxyimino-β-lactams such as ceftazidime and cefepime, which are known as weak AmpC inducers \[[@CIT0030], [@CIT0031]\]. The AmpC-inducing ability of β-lactams could lead to limited choices for their combination use with β-lactamase inhibitors because overproduction of AmpC results in resistance to a variety of β-lactam antibiotics, including third- and fourth-generation cephalosporins.

MECHANISM OF RESISTANCE {#s3}
=======================

Understanding how resistance to new antibiotics develops is an important aspect of drug development because many antibiotics lose their potency with increased and widespread clinical use. Previous investigation comparing the frequency of resistance at drug concentrations of 4 × and 10 × the MIC in *P. aeruginosa* PAO1 strain and detected spontaneous mutation rates of 2.9 × 10^−8^ and \<7.1 × 10^−9^ to cefiderocol, and higher rates of 3.1 × 10^−7^ and 3.4 × 10^−7^ to ceftazidime, respectively \[[@CIT0020]\]. Mutations in the bacterial iron uptake systems associated with a 4-fold elevated cefiderocol MIC (from 0.5 to 2 μg/mL) were identified in this study, although none of the mutations appeared in the responsible iron transporter gene *piuA* \[[@CIT0032]\]. The mutations were identified in the upstream regions of *pvdS* (a gene regulating pyoverdine synthesis), and/or *fecI* (a gene regulating the ferric citrate transporter, FecA). These mutations resulted in an overexpression of pyoverdine and FecA protein, respectively, and conferred a 32-fold increase in cefiderocol MICs, whereas ceftazidime MICs were not affected \[[@CIT0032]\]. In another study, the spontaneous mutation rates for 7 strains (ie, 2 multidrug-resistant \[MDR\] *P. aeruginosa* \[MDRP; 1 IMP-1 producer, 1 ceftazidime resistant\], 2 KPC-producing *K. pneumoniae*, and 3 Enterobacteriaceae \[susceptible to ceftazidime-avibactam\]) ranged from \<1.4 × 10^−8^ to 1.6 × 10^−6^ for cefiderocol and from \<1.0 × 10^−8^ to 2.2 × 10^−5^ for ceftazidime at drug concentrations of 10 × the MIC \[[@CIT0033]\]. No resistant colonies appeared with 4 strains including 1 MDR *P. aeruginosa* and 2 KPC-producing *K. pneumoniae* when tested with cefiderocol. The colonies with ≥8-fold elevated cefiderocol MICs were recovered only from IMP-1--producing MDRP that had the mutations in the upstream region of *pvdS* \[[@CIT0033]\]. However, these resistant mutants did not appear during 72 hours' exposure in an in vitro PD model that simulated human drug exposure of 2 g, over a 3-hour infusion, every 8 hours, implying that the risk of resistance development during treatment with cefiderocol against this strain is low \[[@CIT0033]\]. Resistance acquisition in experiments of daily serial passage for 10 days with 1 MDR *P. aeruginosa* (IMP-1 producer) and 2 KPC-producing *K. pneumoniae* were also studied, and MICs of these 3 strains increased up to 4-fold for cefiderocol \[[@CIT0034]\].

From these data, the potential to develop resistance to cefiderocol is considered to be similar to or lower than that of ceftazidime, regardless of the presence of carbapenemase enzymes. Although information is currently limited on resistance mechanisms to cefiderocol, recent studies identified mechanisms specific to genes related to iron acquisition, and no cross-resistance was observed between cefiderocol and ceftazidime \[[@CIT0035]\]. Further investigations are ongoing to fully understand the resistance mechanisms behind elevated cefiderocol MIC values.

MICROBIOLOGY {#s4}
============

The susceptibility testing method for cefiderocol by broth microdilution involves the use of iron-depleted cation-adjusted Mueller-Hinton broth (ID-CAMHB), which was approved by the Clinical and Laboratory Standards Institute (CLSI) in January 2016 \[[@CIT0036]\]. The purpose of using an iron-depleted medium is to mimic the hypoferric condition that emerges in the host during infection. By using the ID-CAMHB medium for cefiderocol susceptibility testing, highly reproducible (94.2% within ±1 dilution) MIC results were obtained \[[@CIT0037]\]. Additionally, a high correlation between in vitro susceptibility and in vivo efficacy was achieved when using ID-CAMHB. Depletion of iron in the medium represents a very low free iron concentration of ≤0.03 μg/mL, which is normally prepared by the removal of divalent cations using a cation-binding resin followed by replenishment of Mg^2+^, Ca^2+^, and Zn^+^ \[[@CIT0038], [@CIT0039]\]. The Quality Control MIC range of 0.06 μg/mL to 0.5 μg/mL for both *E. coli* American Type Culture Collection (ATCC) 25922 and *P. aeruginosa* ATCC 27853 have also been approved by the CLSI \[[@CIT0038], [@CIT0040]\].

Cefiderocol has a unique antibacterial spectrum against a wide variety of clinically relevant aerobic gram-negative bacteria, including not only Enterobacteriaceae spp such as *Enterobacter* spp, *Klebsiella* spp, *Proteus* spp, *Serratia marcescens*, *Shigella flexneri*, *Salmonella* spp, *Vibrio* spp, and *Yersinia* spp, but also nonfermenting bacterial species such as *Acinetobacter* spp, *Pseudomonas* spp, *Burkholderia* spp, and *Stenotrophomonas maltophilia* \[[@CIT0022]\]. Cefiderocol also has in vitro activity against causative pathogens of respiratory tract infections, such as *Haemophilus* spp, *Moraxella catarrhalis*, and *Bordetella parapertussis*, but shows relatively high MICs (\>4 μg/mL) against *Campylobacter jejuni* and ceftriaxone-resistant *Neisseria gonorrhoeae* among the gram-negative bacteria tested \[[@CIT0022]\]. Importantly, cefiderocol shows high MICs of ≥32 μg/mL against prevalent gram-positive bacteria such as *Staphylococcus aureus* and *Enterococcus faecalis*. Against anaerobic gram-negative or gram-positive bacteria, cefiderocol shows much variation in MICs within genera, from ≤0.031 to \>32 μg/mL, which are higher than MICs of cefepime or meropenem. This variation in the susceptibility of anaerobes may be partly explained by a lower reliance on the siderophore-iron transporter systems for growth under anaerobic conditions \[[@CIT0022]\].

Cefiderocol displays potent in vitro activity with relatively low MICs against the drug-resistant gram-negative pathogens producing multiple β-lactamases, including extended-spectrum β-lactamases, AmpC, and both serine- and metallo-carbapenemases \[[@CIT0022]\]. The MICs of cefiderocol were ≤2 μg/mL against almost all of the clinical isolates producing genetically diverse β-lactamases (ie, CTX-M-14/-15/-27, TEM-10/-26, CMY-2, NDM-1, or IMP-1 in *E. coli*; SHV-5/-18, GES-4, CMY-8/-17, DHA, KPC-2/-3, OXA-48, or NDM-1 in *K. pneumoniae*; VIM-1/-2/-6 or IMP-1 in *P. aeruginosa*; OXA-23/-58 in *A. baumannii*) \[[@CIT0022]\]. Additionally, cefiderocol demonstrated potent activity, with an MIC~90~ (the lowest concentration of the antibiotic at which the growth of 90% of the isolates is inhibited) of 1 μg/mL, against Enterobacteriaceae strains producing IMP-6, a subtype of IMP MBL conferring a paradoxical phenotype of imipenem susceptibility but meropenem resistance \[[@CIT0041]\].

Recently, the emergence of *E. coli* isolates that carry a PBP3 mutation, namely an insertion of 4 amino acids "YRIN" or "YRIK," has been reported \[[@CIT0042]\]. This insertion in the PBP3 gene confers reduced susceptibility to a broad range of β-lactams (eg, ceftazidime, cefepime, and aztreonam), but not to carbapenems. However, cefiderocol susceptibility is reported to be little affected by the YRIN(K) insertion in *E. coli* isolates \[[@CIT0043]\].

Conversely, cefiderocol MICs were affected by a D179Y mutation in the Ω-loop of KPC β-lactamases, which are resistant to ceftazidime-avibactam, in *K. pneumoniae* clinical strains as well as *E. coli* laboratory strains \[[@CIT0044]\].

IN VIVO EFFICACY {#s5}
================

Previous siderophore monobactams (eg, MB-1 or SMC-3176) have not advanced into clinical studies because their in vivo efficacy in preclinical infection models did not correlate with their high in vitro activity \[[@CIT0016], [@CIT0018]\]. This was partially explained by the presence or emergence of adaptive resistance, described in detail in the article by Page \[[@CIT0045]\], which may be due to downregulation of iron transporter receptors, in *P. aeruginosa* clinical isolates used in the in vivo infection models treated with either MB-1 or SMC-3176 \[[@CIT0016], [@CIT0018]\]. In contrast to these findings, cefiderocol treatment demonstrated consistent in vivo efficacy against the same strains of *P. aeruginosa* \[[@CIT0046]\]. Although the siderophore monobactams did not demonstrate the expected in vivo efficacy based on their in vitro potency in the same study \[[@CIT0046]\], a high degree of correlation was noted with cefiderocol using a dose replicating the human pharmacokinetics of cefiderocol \[[@CIT0047]\]. Additionally, the magnitude of % fraction of time over MIC (ƒT/MIC) associated with 1-log~10~ reduction in bacterial load was 81.9% ± 18.3% in a neutropenic murine thigh infection model using *P. aeruginosa* strains (n = 8), which had previously displayed variable in vivo efficacy against MB-1 and SMC-3176 \[[@CIT0047]\].

Furthermore, several in vivo mouse models have demonstrated that cefiderocol is efficacious against a number of pathogenic gram-negative bacteria, including carbapenem-resistant strains. In mouse lung infection models infected with carbapenem-resistant *P. aeruginosa* (CRPA), carbapenem-resistant *A. baumannii* (CRAB), KPC-producing *K. pneumoniae*, or *S. maltophilia*, cefiderocol treatment, in contrast to meropenem treatment, proved to be bactericidal \[[@CIT0048], [@CIT0049]\]. Cefiderocol is also efficacious in other infection models such as the systemic (intraperitoneal) infection model with CRPA, CRAB, *S. maltophilia*, or *Burkholderia cepacia*, or the urinary tract infection model with Enterobacteriaceae spp, and the subcutaneous abscess model with *K. pneumoniae* or *A. baumannii* \[[@CIT0050]\]. Overall, cefiderocol time-dependent in vivo efficacy in various preclinical infection models has been established for carbapenem-resistant pathogens, which was predicted by its in vitro potency and supported by a reliable PK/PD profile. Safety information on cefiderocol is discussed by Katsube et al \[[@CIT0051]\] and Echols et al \[[@CIT0052]\] in this supplement.

CONCLUSIONS {#s6}
===========

Cefiderocol is a novel parenteral cephalosporin antibiotic with siderophore--iron binding properties as well as intrinsic structural stability to a wide range of serine- and metallo-β-lactamases, including clinically relevant carbapenemases. Several in vitro and in vivo studies have demonstrated that this innovative drug has the potential to overcome all 3 mechanisms of β-lactam resistance, including carbapenem resistance increasingly observed in gram-negative bacterial infections. The emergence of resistance to cefiderocol does not appear to be higher than that of other β-lactam antibiotics, and because of its multiple characteristics described above, resistance may be less of a threat to the utility of cefiderocol. Robust preclinical studies in infection models, including urinary tract and systemic infections, established the in vivo efficacy of cefiderocol, which was not demonstrated with earlier monobactam conjugates. With the likely continued emergence and spread of β-lactam resistance mechanisms, cefiderocol could play an important role in future antibacterial therapy against problematic gram-negative bacteria, particularly MBL-producing carbapenem-resistant Enterobacteriaceae, as well as MDR or carbapenem-resistant *P. aeruginosa* and MDR or carbapenem-resistant *A. baumannii*.
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